Similar fruits can grow in the most disparate soils. So it would seem when one considers the origins of Keytruda and Opdivo, the twin shining stars in the modern immuno-oncology firmament, owned by Merck and Co and Bristol-Myers Squibb, respectively.
Keytruda And The Surprising Fruits Of M&A
Similar fruits can grow in the most disparate soils. So it would seem when one considers the origins of Keytruda and Opdivo, the twin shining stars in the modern immuno-oncology firmament, owned by Merck and Co and Bristol-Myers Squibb, respectively.
More from Anticancer
More from Therapy Areas
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.